Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring.
The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.il
Avichai
A
Shimoni
Arnon
A
Nagler
D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D020714:Maximum Tolerated Dose; D008991:Monitoring, Physiologic / Q000379:methods*; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine